Business
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, devel...
About this update from Viridian Metals Inc
[{"type":"text","content":"Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock. Viridian is selling a total of 11,425,000 shares of common stock at a public offering price of $22.00 per share. In addition, Viridian has granted the underwriters a 30-day option to purchase an additional 1,713,750 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Viridian from the offering are expected to be approximately $251,350,000, before deducting underwriting discounts and commissions and offering expenses payable by Viridian and assuming no exercise of the underwriters’ option to purchase additional shares.\n \n\n All of the shares to be sold in the underwritten public offering are being offered by Viridian. The offering is expected to close on or about October 23, 2025, subject to customary closing conditions.\n \n\n Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock, together with its cash, cash equivalents and short-term investments, to fund the company’s commercial launch activities related to veligrotug and VRDN-003 and research and development activities, as well as for working capital and general corporate purposes.\n \n\n Jefferies, Leerink Partners, Evercore ISI and Stifel are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as co-manager for this offering.\n \n\n A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on September 5, 2025. A final prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sal...